Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

SELL
$592.2 - $792.28 $59,220 - $79,228
-100 Reduced 3.34%
2,894 $2.25 Million
Q4 2023

Jan 30, 2024

SELL
$525.19 - $619.13 $10,503 - $12,382
-20 Reduced 0.66%
2,994 $1.75 Million
Q3 2023

Oct 25, 2023

BUY
$434.7 - $599.3 $27,820 - $38,355
64 Added 2.17%
3,014 $1.62 Million
Q2 2023

Jul 13, 2023

SELL
$350.74 - $468.98 $10,171 - $13,600
-29 Reduced 0.97%
2,950 $1.38 Million
Q1 2023

May 03, 2023

BUY
$310.63 - $364.82 $31,063 - $36,482
100 Added 3.47%
2,979 $1.02 Million
Q4 2022

Jan 12, 2023

BUY
$321.55 - $374.67 $9,324 - $10,865
29 Added 1.02%
2,879 $0
Q3 2022

Nov 08, 2022

SELL
$296.48 - $337.87 $16,306 - $18,582
-55 Reduced 1.89%
2,850 $922,000
Q1 2022

May 04, 2022

BUY
$234.69 - $291.66 $16,662 - $20,707
71 Added 2.51%
2,905 $832,000
Q4 2021

Jan 24, 2022

BUY
$224.85 - $279.04 $56,212 - $69,760
250 Added 9.67%
2,834 $783,000
Q2 2021

Jul 26, 2021

SELL
$180.55 - $233.54 $55,248 - $71,463
-306 Reduced 10.59%
2,584 $593,000
Q1 2021

May 07, 2021

BUY
$164.32 - $212.72 $32,864 - $42,544
200 Added 7.43%
2,890 $540,000
Q2 2020

Aug 03, 2020

BUY
$136.42 - $164.18 $7,503 - $9,029
55 Added 2.09%
2,690 $442,000
Q1 2020

Apr 27, 2020

SELL
$119.05 - $147.35 $22,976 - $28,438
-193 Reduced 6.82%
2,635 $366,000
Q4 2019

Feb 03, 2020

BUY
$106.92 - $132.43 $53,460 - $66,215
500 Added 21.48%
2,828 $372,000
Q2 2019

Aug 06, 2019

SELL
$110.79 - $129.32 $6,647 - $7,759
-60 Reduced 2.51%
2,328 $258,000
Q1 2019

May 13, 2019

SELL
$111.31 - $131.02 $19,034 - $22,404
-171 Reduced 6.68%
2,388 $310,000
Q4 2018

Jan 29, 2019

BUY
$105.9 - $118.64 $44,901 - $50,303
424 Added 19.86%
2,559 $296,000
Q3 2018

Nov 05, 2018

BUY
$85.86 - $107.31 $183,311 - $229,106
2,135 New
2,135 $229,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $749B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Crescent Grove Advisors, LLC Portfolio

Follow Crescent Grove Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Crescent Grove Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Crescent Grove Advisors, LLC with notifications on news.